Compounded infliximab (Ref: 2020/S 209-511772)

The framework agreement is for the provision of compounded infliximab. This entails suppliers sourcing the product from the manufacturer and compounding it, under aseptic conditions, into an appropriate infusion device and supplying to the trust ready for use by a clinician. The framework is split into three lots for the three available brands of infliximab; Inflectra, Remicade and Remsima respectively.

Framework Agreement